PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 126 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,421,422 | -24.5% | 1,681,149 | +1.4% | 0.37% | -23.5% |
Q2 2023 | $5,853,428 | -2.3% | 1,658,195 | -14.4% | 0.49% | +17.0% |
Q1 2023 | $5,988,692 | -6.1% | 1,938,088 | +28.5% | 0.42% | -25.1% |
Q4 2022 | $6,377,414 | +78.7% | 1,507,663 | +0.1% | 0.56% | +80.6% |
Q3 2022 | $3,568,521 | -12.7% | 1,505,705 | +4.9% | 0.31% | +6.2% |
Q2 2022 | $4,089,969 | -0.3% | 1,435,077 | +0.7% | 0.29% | -7.6% |
Q1 2022 | $4,102,992 | +20.7% | 1,424,650 | +27.4% | 0.32% | +45.2% |
Q4 2021 | $3,398,410 | +21.8% | 1,117,898 | +180.9% | 0.22% | +11.9% |
Q3 2021 | $2,789,559 | +467.4% | 397,940 | +583.1% | 0.19% | +59.0% |
Q1 2020 | $491,638 | -42.9% | 58,251 | +37.7% | 0.12% | -73.8% |
Q4 2018 | $860,825 | -13.4% | 42,301 | +95.2% | 0.47% | +6.9% |
Q3 2018 | $993,615 | -29.8% | 21,671 | -9.4% | 0.44% | -32.6% |
Q2 2018 | $1,415,105 | -9.3% | 23,924 | +4.4% | 0.65% | -10.8% |
Q1 2018 | $1,559,978 | -71.1% | 22,924 | -58.1% | 0.72% | -76.7% |
Q4 2017 | $5,402,054 | – | 54,649 | – | 3.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 207,500 | $21,609,000 | 4.97% |
WEATHERBIE CAPITAL, LLC | 250,296 | $26,066,000 | 2.47% |
Redmile Group, LLC | 172,092 | $17,922,000 | 2.14% |
Tekla Capital Management LLC | 185,820 | $19,351,000 | 1.93% |
Iguana Healthcare Management, LLC | 35,000 | $3,645,000 | 1.68% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $592,210,000 | 1.62% |
Atika Capital Management LLC | 11,350 | $1,182,000 | 1.01% |
Eventide Asset Management | 44,900 | $4,676,000 | 0.73% |
Ghost Tree Capital, LLC | 11,330 | $1,180,000 | 0.70% |
BB BIOTECH AG | 117,991 | $12,288,000 | 0.63% |